ADMA Biologics (NASDAQ:ADMA) Stock Price Up 6.1% - Is It Time to Invest?

ADMA Biologics, Inc. (NASDAQ:ADMA) experienced a notable increase of 6.1% in its stock price during trading on Wednesday, reaching a high of $19.91 before closing at $19.85. In total, approximately 2,397,523 shares changed hands, which represents a decrease of 28% from the average daily trading volume of 3,320,496 shares. The stock had closed the previous day at $18.71.

Get ADMA Biologics alerts:

Insights from Analysts

• There May Still Be Time to Get in on These 3 Trending Biotechs

In a separate analysis, Cantor Fitzgerald maintained an "overweight" rating for ADMA Biologics and set a price target of $25.00 per share, as mentioned in a report released on March 4th.

ADMA Biologics Trading Gains

Currently, the company has a debt-to-equity ratio of 0.48, along with a quick ratio of 3.26 and a current ratio of 7.09. Its market capitalization stands at approximately $4.74 billion, with a price-to-earnings ratio of 71.57 and a beta of 0.60. The 50-day moving average for the stock is $16.67 and the 200-day moving average is $17.98.

Institutional Investments in ADMA Biologics

Recent trading activity shows that several institutional investors have been adjusting their holdings in ADMA Biologics. For instance, Natixis Advisors LLC purchased a new stake worth $345,000 during the third quarter. Similarly, Mutual of America Capital Management LLC acquired shares valued around $701,000. Thrivent Financial for Lutherans added a position valued at approximately $3,802,000, while First Turn Management LLC invested about $13,293,000. Lastly, Aviance Capital Partners LLC bought shares worth about $229,000. Currently, institutional and hedge fund investors hold 75.68% of the company's stock.

About ADMA Biologics

ADMA Biologics, Inc. operates in the biopharmaceutical sector, focusing on the development, manufacturing, and marketing of specialty plasma-derived biologics. These products are intended to treat immune deficiencies and infectious diseases both in the United States and internationally. The company's product lineup includes BIVIGAM, an intravenous immune globulin (IVIG) indicated for primary humoral immunodeficiency (PI); ASCENIV, another IVIG product for treating PI; and Nabi-HB, aimed at addressing acute exposure to blood containing Hepatitis B surface antigen and other related exposures.

Further Reading

• Five stocks we like better than ADMA Biologics
• What is the Dow Jones Industrial Average (DJIA)?
• What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
• Short Selling - The Pros and Cons
• Alphabet’s Officially In A Bear Market—Time To Buy?
• CD Calculator: Certificate of Deposit Calculator
• D-Wave and Quantum Supremacy: Implications For Investors

This news report was crafted using advanced technology and financial data to ensure quick and accurate dissemination of information. It has been reviewed by an editorial team for quality assurance.

Considering an Investment in ADMA Biologics?

If you are thinking of investing in ADMA Biologics, it might be prudent to look into various expert opinions before making a decision.

Market analysts closely monitor the stocks recommended by top-tier analysts and compare them against ADMA Biologics. Currently, while ADMA has a Buy rating, there are five other stocks that analysts recommend as better investment options.

View The Five Stocks Here

stocks, biotechs, investment